The Effects of a Pre-packaged, Portion Controlled Meal Plan on Type 2 Diabetes and Glycemic Control: A Comparison Study

NCT ID: NCT01260337

Last Updated: 2013-07-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-03-31
• Study Completion Date: 2011-08-31

Brief Summary

The purpose of this research study to find out whether a pre-packaged, portion controlled diet with a group behavior modification program or group diabetes support and education, is a safe and effective way for people with type 2 diabetes to lose weight and manage their diabetes.

Detailed Description

Eligible volunteers are randomly assigned to a treatment group consisting of a pre-packaged, portion controlled meal plan plus a group behavior modification program or to a control group that consists of a group diabetes support and education (DSE) program. Random assignment will be stratified by whether or not a subject is taking insulin at baseline, which will be included as a covariate in all subsequent analyses. Treatment assignments are unmasked. At the end of 24 weeks both groups will have completed 9 group sessions (weeks 0, 1, 2, 4, 8, 12, 16, 20 and 24). At week 16, each participant will meet individually with the study physician to review their progress to date. These meetings will take place at the week 16 group visit. The PCD program is aimed at achieving and maintaining a decrease in weight and providing a group behavior modification program from 0-24 weeks. The DSE program is aimed at providing diabetes support and education from weeks 0-24. A Certified Diabetes Educator (CDE) will review the effects of diet and weight loss, exercise, and medications on blood glucose levels among all participants at the individual session before any changes in dietary intake or exercise are prescribed. Participants will be counseled on strategies to prevent hypoglycemia and will be given a blood glucose meter and strips and instructed to measure their blood glucose at least two times per day while participating in the study. In addition, the causes, symptoms and treatment of hypoglycemia will be reviewed including when to contact their health care provider.

Conditions

Obesity

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Diabetes Support and Education (DSE)

Group Type: ACTIVE_COMPARATOR

Diabetes Support and Education

Intervention Type: OTHER

The DSE groups will consist of educational sessions offered for diabetes support and education which will include sessions on diet/nutrition, exercise, foot care and living with diabetes.

Portion controlled diet (PCD)

behavior modification

Group Type: EXPERIMENTAL

Portion controlled diet

Intervention Type: BEHAVIORAL

Participants learn skills for changing nutritional and lifestyle habits and diabetes management follow a program that includes eating a pre-packaged, portion controlled meal for weight loss in addition to attending the behavior modification groups

Interventions

Portion controlled diet

Participants learn skills for changing nutritional and lifestyle habits and diabetes management follow a program that includes eating a pre-packaged, portion controlled meal for weight loss in addition to attending the behavior modification groups

Intervention Type: BEHAVIORAL

Diabetes Support and Education

The DSE groups will consist of educational sessions offered for diabetes support and education which will include sessions on diet/nutrition, exercise, foot care and living with diabetes.

Intervention Type: OTHER

Other Intervention Names

PCD; DSE

Eligibility Criteria

Inclusion Criteria

1. Type 2 diabetic men and non-pregnant or non-lactating women between the ages of 21 to 75

2. BMI ≥ 25 and ≤ 50

3. Subjects must be willing to comply with all study-related procedures

4. Participant with screening HbA1C ≥ 6.5 and <12.0.

Exclusion Criteria

1. Use of Byetta (exenatide) or Symlin (pramlintide acetate) for diabetic control< 6 months. Participants must be stable on all other medications for at least 3 months for inclusion. If a participant is on a medication for less than 3 months and the study physician determines the medications will not affect the study outcomes (weight, glycemic control, etc), they can be enrolled (excluding hypertension or cholesterol medications).

2. BMI ≤24.9 or ≥ 50.1

3. Participation in another formal weight loss program within last 6 months

4. Weight loss > 5 kg during the last 6 months

5. Participation in Diabetes Support and Education Program or other formal diabetes education program within last 6 months

6. Uncontrolled hypertension (systolic blood pressure > 180 or diastolic blood pressure > 100 mmHg). Participants on medication treating hypertension for at least three months are allowable.

7. Known atherosclerotic cardiovascular disease

8. History of congestive heart failure

9. History of a non-skin malignancy within the previous 5 years

10. Any major active rheumatologic, pulmonary, hepatic, renal, dermatologic disease or inflammatory condition

11. History of testing HIV positive

12. History of alcohol or drug abuse

13. Weight-loss inducing medications or dietary supplements within 3 months prior to enrollment.

14. Participation in any weight loss study or investigational drug study within 6 weeks prior to the screening

15. Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.

16. Participants taking anti-depressants (SSRI's are allowed except for bupropion [Wellbutrin]) , mood stabilizers, anti-psychotics, and psychiatric medications treating any mood, psychological or psychiatric condition. Refer to Appendix 1 for medication exclusion list.

17. Participants with screening triglycerides above 500 mg

18. Uncontrolled Dyslipidemia as defined by screening LDL cholesterol of ≥ 160 mg/dL. Participants on medication treating dyslipidemia for at least 3 months are allowable.

19. Any female who tests positive on a urine pregnancy test or who reports being pregnant at screening

20. Gastrointestinal Disorders (gallbladder disease, Crohn's disease, Irritable bowel syndrome, and any GI disease that affects malabsorption).

21. An allergy to certain foods that cannot be avoided due to the nature of the packaged foods such as, but not limited to nuts, dairy, gluten, etc.

22. Non-medical related dietary restrictions, such as vegetarians

23. Neuropathy that interferes with exercise.

24. Smoking or tobacco use

25. Previous weight loss surgery.

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Nutrisystem, Inc.

INDUSTRY

Sponsor Role: collaborator

University of Pennsylvania

OTHER

Sponsor Role: collaborator

Temple University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Gary D Foster, PhD

Role: PRINCIPAL_INVESTIGATOR

Temple University, Center for Obesity Research and Education

Locations

University of Pennsylvania, Center for Weight and Eating Disorders

Philadelphia, Pennsylvania, United States

Temple University, The Center for Obesity Research and Education

Philadelphia, Pennsylvania, United States

Countries

United States

References

Foster GD, Borradaile KE, Vander Veur SS, Leh Shantz K, Dilks RJ, Goldbacher EM, Oliver TL, Lagrotte CA, Homko C, Satz W. The effects of a commercially available weight loss program among obese patients with type 2 diabetes: a randomized study. Postgrad Med. 2009 Sep;121(5):113-8. doi: 10.3810/pgm.2009.09.2046.

Reference Type: BACKGROUND

PMID: 19820280 (View on PubMed)

Related Links

http://www.med.upenn.edu/weight/research.shtml

Center for Weight and Eating Disorders

Other Identifiers

12987

Identifier Type: -

Identifier Source: org_study_id